ONCOSUR AVALOX Study: Identification of Potential Factors with the Selection of First-line Bevacizumab+Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer

Trial Profile

ONCOSUR AVALOX Study: Identification of Potential Factors with the Selection of First-line Bevacizumab+Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms ONCOSUR AVALOX
  • Most Recent Events

    • 11 Dec 2015 New trial record
    • 01 Dec 2015 Results published in the Anticancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top